Results 221 to 230 of about 86,303 (320)

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Artificial Intelligence for Organoids Multidimensional Assessment

SmartMat, Volume 6, Issue 3, June 2025.
This review provides a comprehensive analysis and discussion of the current applications of artificial intelligence (AI) technologies in the evaluation of organoids. It summarizes and synthesizes the primary methods and standards for organoid assessment, offering new insights for researchers engaged in the interdisciplinary field of AI and organoid ...
Yulin Mo, Jian Wang, Huijian Yang, Long Bai, Ke Xu, Jiacan Su   +5 more
wiley   +1 more source

Multiomic analysis of human kidney disease identifies a tractable inflammatory and pro-fibrotic tubular cell phenotype. [PDF]

Nat Commun
Reck M, Baird DP, Veizades S, Sutherland C, Bell RMB, Hur H, Cairns C, Janas PP, Campbell R, Nam A, Yang W, Schurman N, Williams C, O'Sullivan E, Beniazza M, Corsinotti A, Bellamy C, Hughes J, Laird A, Denby L, Chandra T, Ferenbach DA, Conway BR.   +22 more
europepmc   +1 more source

Isoliquiritigenin Promotes the Repair of High Uric Acid‐Induced Vascular Injuries

Smart Medicine, Volume 4, Issue 2, June 2025.
High uric acid‐induced vascular injuries are always accompanied with hyperuricemia, for which seeking for effective safety drugs is an urgent and crucial problem that needs to be solved. Here, we have successfully screened isoliquiritigenin out from multiplex traditional Chinese medicine monomers in promoting the repair of high uric acid‐induced ...
Hongyan Zhou, Xinyu Song, Yingying Tian, Lili Zhao, Jingyi Yang, Fangfu Ye, Ting Cao, Jiayu Zhang   +7 more
wiley   +1 more source

Tubule-Specific Compensatory Responses to Cpt1a Deletion in Aged Mice. [PDF]

Kidney360
Funk SD, Kern JT, Viquez OM, Sulvaran-Guel E, Koenitzer JR, Feola KC, Blum JS, Zent R, Humphreys BD, Huen SC, Gewin LS.   +10 more
europepmc   +1 more source

An unexpected ally in heart failure treatment: Unlocking the potential of sodium‐glucose cotransporter 2 inhibitors across patient subpopulations

ESC Heart Failure, Volume 12, Issue 3, Page 1532-1534, June 2025.
Sander Trenson, Mateusz Sokolski
wiley   +1 more source

Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor

Clinical and Translational Science, Volume 18, Issue 6, June 2025.
ABSTRACT Epaminurad, a novel uricosuric agent, exhibits potent inhibitory activity against the human uric acid transporter. This study aimed to investigate the effects of renal function and food intake on the pharmacokinetic, pharmacodynamic, and safety characteristics of 9 mg epaminurad. This study was designed as a phase 1, partially randomized, open‐
Seo Yeong Park, Jun Gi Hwang, Sung Kweon Cho, Min Kyu Park   +3 more
wiley   +1 more source

FATP1-mediated fatty acid uptake in renal tubular cells as a countermeasure for hypothermia. [PDF]

J Mol Med (Berl)
Horioka K, Tanaka H, Watanabe S, Yamada S, Takauji S, Hayakawa A, Isozaki S, Okaba K, Ishii N, Motomura A, Inoue H, Addo L, Yajima D, Takahashi Y, Druid H, Pakanen L, Porvari K.   +16 more
europepmc   +1 more source

Obesity‐related glomerulopathy: How it happens and future perspectives

Diabetic Medicine, Volume 42, Issue 6, June 2025.
Abstract Obesity‐related glomerulopathy (ORG) is an emerging complication of excess adiposity. Its incidence rises alongside the obesity pandemic. Up to 40% of individuals can be affected by ORG, irrespective of the status of glomerular filtration rate and albuminuria.
Jian‐Wen Samuel Lee‐Boey, Jia‐Kai Tan, Zhan‐Foong Lim, Francesco Zaccardi, Kamlesh Khunti, Majid Ezzati, Edward W. Gregg, Lee‐Ling Lim   +7 more
wiley   +1 more source

Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks

Diabetes, Obesity and Metabolism, Volume 27, Issue 6, Page 2920-2939, June 2025.
Abstract Glycaemic therapy in type 1 diabetes (T1D) is focused on insulin, with the majority of studies investigating different insulin preparations, delivery devices and dosing accuracy methods. While insulin deficiency is the key mechanism for hyperglycaemia in T1D, individuals with this condition can also develop insulin resistance (IR), making ...
Ahmad M. Rajab, Sam Pearson, Ramzi A. Ajjan   +2 more
wiley   +1 more source